✦ LIBER ✦

The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder

✍ Scribed by Fishbain, David A.; Detke, Michael J.; Wernicke, Joachim; Chappell, Amy S.; Kajdasz, Daniel K.

Book ID: 120658132
Publisher: Informa plc
Year: 2008
Tongue: English
Weight: 167 KB
Volume: 24
Category: Article
ISSN: 0300-7995
DOI: 10.1185/03007990802429627

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Assessment of depressive symptoms and fu

Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol

✍ Tina Marie Myers Oakes; Adam L. Myers; Lauren B. Marangell; Jonna Ahl; Apurva Pr 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 3 views

Objective Return of functional ability is a central goal in the treatment of major depressive disorder. We conducted two trials with the same protocol that was designed to assess functioning after 8 Weeks of treatment with duloxetine. Methods The a priori primary outcome was improvement in the Hamil

Efficacy and safety of duloxetine for tr

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

✍ I. Jon Russell; Philip J. Mease; Timothy R. Smith; Daniel K. Kajdasz; Madelaine 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 608 KB

Efficacy and tolerability of the novel t

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial

✍ Pierre Tran; Phil Skolnick; Pal Czobor; N.Y. Huang; Mark Bradshaw; Anthony McKin 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 297 KB

Concerns about data reporting and interp

Concerns about data reporting and interpretation in “Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial”

✍ David M. Marks; Jonathan S. Abramowitz; Glen I. Spielmans 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 84 KB